Skip to content
ewggd
Gaucher Disease
ewggd
  • Home
  • About EWGGD
    • Mission Statement
    • Activities
    • Board Members
    • History
    • Patient Organisations
  • Gaucher Disease
  • Membership
  • Education
    • Webinars
    • Presentations
    • Pre-ceptorships
    • EWGGD E-mentor Programme
  • Research and Working Groups
    • Clinical Trials
    • EWGGD Research Projects
    • EWGGD Working Groups
  • Publications & Guidelines
    • EWGGD Newsletter
    • EWGGD Publications
    • Policy Documents and Position Statements
    • Guidelines
  • Advocacy
  • Meetings
  • Member Forum
Search:
  • Home
  • About EWGGD
    • Mission Statement
    • Activities
    • Board Members
    • History
    • Patient Organisations
  • Gaucher Disease
  • Membership
  • Education
    • Webinars
    • Presentations
    • Pre-ceptorships
    • EWGGD E-mentor Programme
  • Research and Working Groups
    • Clinical Trials
    • EWGGD Research Projects
    • EWGGD Working Groups
  • Publications & Guidelines
    • EWGGD Newsletter
    • EWGGD Publications
    • Policy Documents and Position Statements
    • Guidelines
  • Advocacy
  • Meetings
  • Member Forum

Publications The European Working Group for Gaucher Disease

EWGGD NEWSLETTER

EWGGD PUBLICATIONS

POLICY DOCUMENTS

GUIDELINES

EWGGD Publications

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, et al. Blood Cells Mol Dis. 2018;68:203-208.

 

Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.

Hollak CE, Aerts JM, Belmatoug N, et al. Blood Cells Mol Dis. 2010;44(2):86-7.

 

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

Hollak CE1, vom Dahl S, Aerts JM, et al. Blood Cells Mol Dis. 2010;44(1):41-7.

 

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Cox TM, Aerts JM, Andria G, et al. J Inherit Metab Dis. 2003;26(6):513-26.

 

Management of neuronopathic Gaucher disease: a European consensus.

Vellodi A, Bembi B, de Villemeur et al. J Inherit Metab Dis. 2001 Jun;24(3):319-27.

Policy Documents and Position Statements

EWGGD Code of Practice with Industry

EWGGD Working Group Policy

EWGGD Statement on Home Therapy

Guidelines

Patient-reported outcome measures for patients with Gaucher disease – Shoshana Revel-Vilk, Vesna Aleksovska, Paul Guijt, Tanya Collin-Histed

Symptomatic care of children with non-neuronopathic Gaucher disease – Shoshana Revel-Vilk, Maggy Abdelwah,

© 2019 - 2022 EWGGD | TERMS OF USE

Go to Top
Subscribe to the newsletter